[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-kidney-metabolic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-kidney-metabolic-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,53,84,114,138,174,206,239,265],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053768","atrial-cardiomyopathy-in-patients-with-cardiovascular-kidney-metabolic-syndrome-non-invasive-characterization-100053768",false,"NCT07697469","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization (ATRIO-CKM)","ATRIO-CKM","Inclusion Criteria:\n\n* Adults aged 18 years or older presenting for cardiovascular evaluation Signed written informed consent Agreement with all protocol requirements\n\nExclusion Criteria:\n\n* Missing key data for ACM or CKM classification Hemodynamically significant valvular heart disease (greater than moderate severity) Mechanical or biological valve prostheses Temporary or permanent cardiac pacing Psychiatric pathology Thyroid pathology (active or untreated) Known cardiomyopathies (hypertrophic, dilated, restrictive, or infiltrative) Refusal to participate or inability to comply with protocol requirements","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multiorgan dysfunction and increased risk of atrial fibrillation, stroke, and heart failure. Atrial cardiomyopathy (ACM) - defined as any structural, contractile, or electrical abnormality of the atria - is an increasingly recognized contributor to cardiovascular morbidity and mortality in this population. Despite growing interest in both conditions, their interplay remains poorly understood, limiting effective preventive strategies and risk-stratification approaches for this high-risk group.\n\nCKM staging offers a practical framework for anticipating ACM onset and progression. Because adiposity-driven inflammation, insulin resistance, hypertension, and early kidney injury act as upstream drivers in CKM, the left atrium becomes an early indicator of hemodynamic load and fibrosis - often preceding sustained atrial fibrillation. Early non-invasive detection of ACM across CKM stages could shift care from treating complications to modifying the underlying substrate.\n\nThis prospective observational single-center cohort study aims to phenotype ACM non-invasively across all CKM stages at first diagnosis, using standard 12-lead ECG, advanced transthoracic echocardiography with speckle-tracking, a mechanistically selected biomarker panel (NT-proBNP, MR-proANP, Fetuin-A, FGF23), and cardiac MRI.\n\nAdults aged 18 years or older presenting for cardiovascular evaluation are enrolled and grouped as CKM with ACM (study group) versus CKM without ACM (control group). All participants undergo a single standardized baseline evaluation including clinical examination, 12-lead ECG with Bayés interatrial block grading, comprehensive laboratory panel, and advanced echocardiography including left atrial global longitudinal strain by speckle-tracking.\n\nPrimary objective: characterize the relationship between ACM and CKM syndrome stages using non-invasive parameters at first diagnosis. Secondary objectives include assessment of clinical, biological, ECG, and imaging profiles of ACM in CKM; evaluation of left atrial function across CKM stages; examination of Bayés interatrial block correlations and the impact of SGLT2 inhibitors and GLP-1 receptor agonists on left atrial remodeling in HFpEF; and identification of independent ACM risk factors incorporating the full biomarker panel.\n\nStatistical analyses include multivariable logistic regression, biomarker ROC analyses, and penalized regression for derivation of a pragmatic ACM risk score with internal validation. Expected outputs include prevalence estimates, effect sizes for ACM and CKM joint categories, biomarker performance metrics, and a clinic-ready checklist for risk-stratified prevention in outpatient settings.",[25,26,27,28,29],"Cardiovascular-Kidney-Metabolic Syndrome","Atrial Cardiomyopathy","Atrial Fibrillation","Chronic Kidney Disease","Metabolic Syndrome",[31,32,33,34,35,36,37,38,39,27,28],"atrial cardiomyopathy","CKM syndrome","on-invasive evaluation","atrial remodeling","Bayés interatrial block","speckle tracking","Fetuin-A","MR-proANP","FGF23","NOT_YET_RECRUITING","2026-07-05",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":21},"2026-07-10",{"date":48,"type":21},"2028-04",{"name":50,"class":51},"Grigore T. Popa University of Medicine and Pharmacy","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":52},"100640319","ai-chatbot-enabled-epro-symptom-monitoring-and-self-management-for-early-cardiovascular-kidney-metabolic-syndrome-100640319","NCT07577284","AI Chatbot-Enabled ePRO Symptom Monitoring and Self-Management for Early Cardiovascular-Kidney-Metabolic Syndrome","Inclusion Criteria:\n\n* Adults ≥40 years\n* Classified as having stage CKM syndrome (stage 1-2)\n* Receiving outpatient care\n* Able to communicate in Mandarin\u002FTaiwanese, and\n* Having access to a smartphone\u002Ftablet\n\nExclusion Criteria:\n\n* End-stage kidney disease requiring dialysis or are listed for kidney transplantation\n* Have terminal illness (\\\u003C6 months life expectancy)\n* Have significant cognitive impairment\n* Currently enrolled in another interventional study targeting cardiovascular-kidney-metabolic syndrome or multimorbidity","40 Years",{"count":61,"type":21},72,"INTERVENTIONAL",[64],"NA","This randomized clinical trial aims to evaluate whether an AI chatbot-enabled, nurse-led electronic patient-reported outcome (ePRO) intervention can improve symptom management and self-care in adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. The study will also assess the safety and feasibility of the intervention. Researchers will investigate whether the program reduces symptom burden, improves patient activation and health literacy, and lowers healthcare utilization such as emergency department visits and hospitalizations compared with usual ePRO monitoring alone. A total of 72 participants will be randomly assigned to either an intervention group, which receives weekly AI chatbot-supported symptom monitoring combined with nurse-led feedback and self-management support, or a control group receiving ePRO monitoring without feedback. Participants will complete PROMIS-29 assessments weekly and attend study evaluations at baseline, 3 months, and 6 months, while clinical outcomes and healthcare use are tracked through electronic medical records.",[67],"Cardiovascular Kidney Metabolic Syndrome",[69,70,71,72,73,74],"artificial intelligence","Chatbot","electronic patient-reported outcomes","patient activation","randomized controlled trial","cardiovascular kidney metabolic syndrome","2026-05-05",{"date":77,"type":44},"2026-05-11",{"date":79,"type":21},"2026-05-30",{"date":81,"type":21},"2029-07-31",{"name":83,"class":51},"Taipei Medical University",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":94,"studyType":22,"phases":4,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":52},"100635008","study-on-construction-of-whole-lifecycle-cohort-big-data-management-and-clinical-prognosis-of-cardio-renal-metabolic-ckm-syndrome-100635008","NCT07547098","Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome","CKM-LCBP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.\n* Cardiovascular disease, kidney disease, metabolic disease, or key examination\u002Flaboratory information supporting CKM phenotyping.\n* Willingness to participate and provision of written informed consent.\n* Ability to complete baseline assessment and follow-up.\n* Full civil capacity and ability to understand study information.\n\nExclusion Criteria:\n\n* Refusal to provide written informed consent.\n* Severe psychiatric disease or cognitive impairment precluding participation.\n* End-stage disease with expected survival less than 1 year.\n* Long-term absence more than 6 months preventing reliable follow-up.\n* Participation in another clinical study that may interfere with endpoint adjudication.\n* Missing key fields preventing linkage of examinations, imaging, and outcomes.","80 Years",{"count":93,"type":21},8000,"5 Years","This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and\u002For metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.",[97,28,98,99],"Cardiovascular Diseases (CVD)","Metabolic Diseases","Cardiovascular-kidney-metabolic Syndrome",[32,101,102,103],"Cardiovascular-Kidney-Metabolic","Patient registry","Real-world data","RECRUITING","2026-04-19",{"date":107,"type":44},"2026-04-23",{"date":109,"type":44},"2026-03-01",{"date":111,"type":21},"2031-02-28",{"name":113,"class":51},"First Affiliated Hospital of Fujian Medical University",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":62,"phases":123,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100627699","construction-of-a-comprehensive-health-management-platform-for-patients-with-cardiovascular-kidney-metabolic-syndrome-100627699","NCT07452029","Construction of a Comprehensive Health Management Platform for Patients With Cardiovascular-Kidney-Metabolic Syndrome","Inclusion Criteria:\n\n* CKM stage 0-2 as defined by the American Heart Association CKM diagnostic guidelines\n* Age 18-75 years\n* Able to use a smartphone and wearable activity tracker\n* Willing to sign informed consent and attend scheduled follow-up visits\n\nExclusion Criteria:\n\n* CKM stage 3-4\n* Acute or critically ill conditions requiring hospitalization\n* Malignant tumors or any active cancer under treatment","75 Years",{"count":122,"type":21},150,[64],"Cardiovascular-Kidney-Metabolic (CKM) syndrome underscores the pathophysiologic interplay among metabolic risk factors, chronic kidney disease (CKD) and the cardiovascular system. This crosstalk precipitates multi-organ dysfunction, increases adverse cardiovascular events, and imposes heavy familial and socioeconomic burdens. Building a health-management platform within research wards is therefore urgent. Such a platform is the pivotal venue for assessment, monitoring, intervention and follow-up in continuous care.\n\nLeveraging the existing health-management system of the Health Screening Center at Peking University Third Hospital, the investigators will develop a comprehensive CKM platform that integrates systemic inflammatory biomarkers, cardiovascular early-warning algorithms, and personalized diet-and-exercise prescriptions. The system will provide cyclic management encompassing evaluation, guidance, monitoring, feedback and longitudinal follow-up.\n\nA randomized controlled trial with two-year prospective follow-up will enroll patients at CKM stages 0-2 to evaluate clinical improvement, quality of life, dietary behavior and physical activity after platform enrollment. The project will enable early identification of high-risk individuals, deliver precision management, maximize data utility, and offer a novel research-ward model that addresses mobile-health pain points and closes the CKM care loop.",[25],[127,128,129,25],"Comprehensive Health Management Platform","Mobile Health","Early identification",{"date":131,"type":44},"2026-03-05",{"date":133,"type":21},"2026-03",{"date":135,"type":21},"2027-12",{"name":137,"class":51},"Peking University Third Hospital",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":146,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":62,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100595095","food-and-fitness-with-medicine-ffwm-100595095","NCT07027995","Food and Fitness With Medicine (FFWM)","Food and Fitness With Medicine","FFWM","Inclusion Criteria:\n\n* Diagnosis of at least one of the following conditions: hypertension, type 2 diabetes, hyperlipidemia, chronic kidney disease, and\u002For metabolic syndrome.\n* At least 18 years of age at the time of signing consent.\n* Participants must have reliable transportation to attend Exercise is Medicine sessions.\n* Access to an internet-enabled device.\n* No objections to online grocery shopping, home food deliveries, or nutrition counseling.\n* Residence meets Instacart delivery requirements (e.g., non-institutionalized).\n* Participant is willing to use a personal credit card for Instacart back-up payments.\n* Participants must speak English to be able to consent and engage in FIM and EIM programs.\n* Participant has been clinically prescribed GLP-1RA's.\n\nExclusion Criteria:\n\n* Conditions that impact digestion, metabolism, or food intake (e.g. surgical loss of esophagus, stomach, or colon, pancreatic dysfunction, bariatric surgery, brain surgery that alters cognition, etc.).\n* Participants with uncontrolled mental illness disorders (e.g., schizophrenia, bipolar disorder, major depression, etc.) that are not well-managed or controlled through treatment, as determined by the study team.\n* Familial history of certain cancers (e.g., multiple endocrine neoplasia, medullary thyroid carcinoma, etc.).\n* Active digestive illnesses (i.e., Celiac disease, irritable bowel syndrome, chronic malabsorption).\n* Comorbidities such as psychiatric or general illness that may put the subject at risk as determined by the investigator\u002Fs.\n* Renal impairment, eGFR \\\u003C 60 ml\u002Fmin\u002F1.73m2\n* Factor which, in the investigator's opinion, is likely to compromise the subject's ability to participate in the study.\n* Recent participation (e.g., 3 months) in other behavioral nutrition trials or programs (i.e., bariatric programs, diabetes education programs).\n* Currently pregnant or planning to become pregnant during the study.\n* Participant is not willing to provide a urine, blood, or stool sample.","FEMALE",{"count":20,"type":21},[64],"Food and Fitness with Medicine (FFWM) is a 24-week randomized controlled trial (RCT) enrolling 200 post-menopausal women (PMW) with stage 2 cardio-kidney metabolic (CKM) syndrome and type-2 diabetes (T2D) within 6 weeks of initiating glucagon-like peptide-1 receptor agonist (GLP-1RAs) to: 1. Examine discontinuation rates of GLP-1RAs (primary outcome); 2. Compare change in American Heart Association (AHA) PREVENT scores (secondary outcome); and 3. Examine the effects of FFWM on biologic mechanisms responsive to weight loss and cardiovascular health (CVH) including dermal carotenoids, body composition and metabolite biomarkers.",[67,151],"Type 2 Diabetes",[153,154,155,156,157,151,158,159,160,161,162,163],"Food is Medicine","Cardiovascular-kidney-metabolic","Exercise is Medicine","Post-menopausal Women","Medically Tailored Groceries","Glucagon-like Peptide 1 Receptor Agonists","Nutrition","Behavior","GLP-1","Weight","Fitness","2026-02-20",{"date":166,"type":44},"2026-02-23",{"date":168,"type":44},"2026-01-14",{"date":170,"type":21},"2029-03",{"name":172,"class":51},"Ohio State University",4,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":146,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":62,"phases":184,"briefSummary":185,"conditions":186,"keywords":194,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":52},"100590349","inspire-her-inspiring-the-heart-and-emotions-for-radical-health-100590349","NCT06966258","Inspire HER: Inspiring the Heart and Emotions for Radical Health","Inclusion Criteria:\n\n* Black women (self-report)\n* Adult ages 30-79 years\n* Stage 2 or greater Cardiovascular-Kidney-Metabolic Syndrome\n* English speaking\n* Lives in Metropolitan Birmingham, AL area.\n\nExclusion Criteria:\n\n\\- Healthcare provider-imposed physical activity limitations.","30 Years","79 Years",{"count":183,"type":21},90,[64],"Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.",[99,187,188,189,190,191,192,193],"Cardiovascular Diseases","Hypertension","Diabetes","Hyperlipidemia","Kidney Disease","Obesity","Smoking",[195,196],"Cardiovascular Risk","Lifestyle intervention","2025-12-19",{"date":199,"type":44},"2025-12-29",{"date":201,"type":44},"2025-11-15",{"date":203,"type":21},"2029-03-31",{"name":205,"class":51},"University of Alabama at Birmingham",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":213,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":216,"studyType":22,"phases":4,"briefSummary":217,"conditions":218,"keywords":224,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":52},"100596262","cardiovascular-kidney-metabolic-syndrome-in-shanghai-zicitizens-100596262","NCT07043166","Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens","Epidemiological Survey and Follow-up of Cardiovascular-Kidney-Metabolic Diseases Among Adults in Shanghai","Inclusion Criteria:\n\n1. The 4,094 residents of Shanghai communities who have been enrolled in the STONE cohort.\n2. Individuals who completed the baseline questionnaire survey, physical examination, and related clinical tests between 2016 and 2017, with complete data records.\n3. Willingness to participate in this follow-up study and provision of informed consent.\n\nExclusion Criteria:\n\n1. Participants who have moved away from their original community and have been living elsewhere for more than two years.\n2. Participants whose contact information has changed or become invalid, resulting in loss of contact (those who remain uncontactable after three attempts to reach out).",true,{"count":215,"type":21},4094,"10 Years","The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants.\n\nThe study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, participants will be categorized based on CKM staging. The follow-up phase will continue until 2035.",[29,189,219,188,220,221,222,223,97,99],"Obesity and Overweight","Dyslipidemia","Thyroid Diseases","Bone Metabolism Disorder","Chronic Kidney Disease(CKD)",[25,225,226,227,228,229],"metabolic disorders","screening","risk factor","evaluation","prediction","2025-08-31",{"date":232,"type":44},"2025-09-08",{"date":234,"type":44},"2025-07-01",{"date":236,"type":21},"2035-12-31",{"name":238,"class":51},"Shanghai Changzheng Hospital",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":251,"studyType":22,"phases":4,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100603051","mechanisms-and-interventions-for-physical-activity-in-frail-cardiovascular-kidney-metabolic-syndrome-patients-a-temporal-self-regulation-approach-100603051","NCT07131488","Mechanisms and Interventions for Physical Activity in Frail Cardiovascular-kidney-metabolic Syndrome Patients: A Temporal Self-Regulation Approach","Research on the Mechanisms and Intervention Strategies for Physical Activity Promotion in Frail Patients With Cardiovascular-Kidney-Metabolic Syndrome From a Temporal Self-Regulation Perspective","CKM","Inclusion Criteria:\n\n* Aged ≥45 years and \\\u003C60 years;\n\nFrailty status assessed by Fried phenotype criteria, including those diagnosed with frailty or pre-frailty;\n\nMeeting AHA guideline criteria for Stage 1-2 CKM syndrome (diagnostic details in Table 1);\n\nAbility to communicate normally and use smartphones or wearable devices;\n\nWillingness to participate in surveys and follow-up;\n\nAdditional Note on PREVENT Equation:\n\nThe PREVENT equation, developed by the American Heart Association (AHA), is a cardiovascular disease (CVD) risk prediction tool. It calculates 10-year CVD risk based on:\n\nAge, sex\n\nTotal cholesterol, HDL-C\n\nSystolic blood pressure, BMI\n\neGFR\n\nHistory of diabetes, smoking\n\nUse of antihypertensive or lipid-lowering medications\n\nExclusion Criteria:\n\n* Severe cognitive impairment (e.g., MMSE score \\\u003C10 or clinical dementia diagnosis);\n\nSevere psychiatric\u002Fpsychological disorders (e.g., schizophrenia, major depressive disorder with suicidal ideation);\n\nAdvanced chronic diseases including:\n\nEnd-stage renal disease (eGFR \\\u003C15 mL\u002Fmin\u002F1.73m² or on dialysis)\n\nMetastatic cancer (stage IV per AJCC criteria)\n\nCardiorespiratory insufficiency (NYHA Class III-IV heart failure or COPD GOLD Stage D)\n\nSevere osteoarthritis (Kellgren-Lawrence Grade 4 with functional limitation)\n\nMajor surgery or acute illness within 3 months (e.g., myocardial infarction, stroke, or major trauma requiring hospitalization);\n\nPhysical disabilities impairing mobility (e.g., amputation, paralysis, or severe Parkinsonism with Hoehn \\& Yahr Stage ≥3).","45 Years","60 Years",{"count":250,"type":21},614,"9 Months","Longitudinal physical activity data and associated factors were collected at baseline (diagnosis), 3-month, 6-month, and 9-month follow-ups in cardiovascular-kidney-metabolic syndrome patients.",[99],[255,256],"Time-limited Self-regulation Theory","physical activity","2025-08-12",{"date":259,"type":44},"2025-08-20",{"date":259,"type":21},{"date":262,"type":21},"2026-10-12",{"name":264,"class":51},"Nanjing Medical University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":213,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":216,"studyType":22,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":52},"100599453","swiss-cardiovascular-kidney-liver-metabolic-cklm-registry-100599453","NCT07084688","Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry","Inclusion Criteria:\n\n* At least 18 years of age\n* Individuals diagnosed with cardiovascular-kidney-metabolic (CKM) syndrome stages 0 to 3 according to the American Heart Association (AHA) or liver disease defined by any of the following:\n\n  * For stage 0: Individuals without overweight\u002Fobesity, metabolic risk factors (normoglycemia, normotension, normal lipid profile), Chronic kidney disease (CKD), or Cardiovascular disease (CVD)\n  * Individuals with overweight\u002Fobesity or dysfunctional adipose tissue, without other metabolic risk factors or CKD\n  * Individuals with metabolic risk factors (hypertriglyceridemia, arterial hypertension, metabolic syndrome, diabetes) or CKD\n  * Subclinical Atherosclerotic cardiovascular disease (ASCVD) or subclinical heart failure (HF) in individuals with excess\u002Fdysfunctional adiposity, other metabolic risk factors, or CKD in the clinical assessment\\[2\\]\n  * Independent of CKM syndrome stages, individual with signs of hepatic steatosis on imaging\n* Willingness to provide informed consent\n\nExclusion Criteria:\n\n* Individuals with CKM syndrome stage 4 according to the AHA\n\n  \\* Individuals with clinical cardiovascular disease including:\n  * History of coronary artery disease, myocardial infarction, coronary artery intervention\n  * History of atrial fibrillation\n  * History of stroke\n  * Symptomatic peripheral artery disease (\\>stage I)\n  * History of symptomatic HF\n  * History of HF hospitalisation\n* Inability to sign informed consent",{"count":272,"type":21},1500,"The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.",[275,99],"Cradiovascular-kidney-liver-metabolic (CKLM) Syndrome",[277,278,279,280,281],"Cardiovascular-kidney-liver-metabolic (CKLM) syndrome","Cardiovascular disease (CVD)","Chronic kidney disease (CKD)","Organ-specific diseases","Cardiovascular-kidney-metabolic (CKM) syndrome","2025-07-17",{"date":284,"type":44},"2025-07-24",{"date":286,"type":21},"2025-07-14",{"date":288,"type":21},"2040-07",{"name":290,"class":51},"University Hospital, Basel, Switzerland"]